We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the JAMA Network |

Computed Tomography Screening for Lung Cancer A High-Value Proposition?

Joshua A. Roth, PhD, MHA1,2,3; Scott D. Ramsey, MD, PhD1,2,3
[+] Author Affiliations
1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
3Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle
JAMA. 2016;315(1):77-78. doi:10.1001/jama.2015.17877.
Text Size: A A A
Published online


This commentary discusses a cost-effectiveness study published in JAMA Oncology that found CT screening for lung cancer would be cost-effective in a Canadian population.

JAMA Oncology

Cost-effectiveness of Lung Cancer Screening in Canada

John R. Goffin, MD, FRCPC; William M. Flanagan, BM; Anthony B. Miller, MD, FRCPC; Natalie R. Fitzgerald, MA; Saima Memon, MBBS, MPH; Michael C. Wolfson, PhD; William K. Evans, MD, FRCPC

Importance The US National Lung Screening Trial supports screening for lung cancer among smokers using low-dose computed tomographic (LDCT) scans. The cost-effectiveness of screening in a publicly funded health care system remains a concern.

Objective To assess the cost-effectiveness of LDCT scan screening for lung cancer within the Canadian health care system.

Design, Setting, and Participants The Cancer Risk Management Model (CRMM) simulated individual lives within the Canadian population from 2014 to 2034, incorporating cancer risk, disease management, outcome, and cost data. Smokers and former smokers eligible for lung cancer screening (30 pack-year smoking history, ages 55-74 years, for the reference scenario) were modeled, and performance parameters were calibrated to the National Lung Screening Trial (NLST). The reference screening scenario assumes annual scans to age 75 years, 60% participation by 10 years, 70% adherence to screening, and unchanged smoking rates. The CRMM outputs are aggregated, and costs (2008 Canadian dollars) and life-years are discounted 3% annually.

Main Outcomes and Measures The incremental cost-effectiveness ratio.

Results Compared with no screening, the reference scenario saved 51 000 quality-adjusted life-years (QALY) and had an incremental cost-effectiveness ratio of CaD $52 000/QALY. If smoking history is modeled for 20 or 40 pack-years, incremental cost-effectiveness ratios of CaD $62 000 and CaD $43 000/QALY, respectively, were generated. Changes in participation rates altered life-years saved but not the incremental cost-effectiveness ratio, while the incremental cost-effectiveness ratio is sensitive to changes in adherence. An adjunct smoking cessation program improving the quit rate by 22.5% improves the incremental cost-effectiveness ratio to CaD $24 000/QALY.

Conclusions and Relevance Lung cancer screening with LDCT appears cost-effective in the publicly funded Canadian health care system. An adjunct smoking cessation program has the potential to improve outcomes.

JAMA Oncol. 2015;1(6):807-813. doi:10.1001/jamaoncol.2015.2472


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.